NEW YORK (GenomeWeb) – Centogene announced today that it has signed an agreement to help Aldeyra Therapeutics identify patients with Sjögren-Larsson Syndrome (SLS) in support of its effort to develop a treatment for the rare genetic disease.

SLS is caused by mutations that adversely affect lipid metabolism, leading to scaly skin, intellectual disability, and spasticity. While there is no approved treatment for the inherited disorder, Aldeyra currently has a drug candidate — reproxalap — under phase II development.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.